raltitrexedreduces

Raltitrexed is a chemotherapy drug used in the treatment of certain types of cancer, primarily advanced colorectal cancer. It is an antimetabolite, specifically a thymidylate synthase inhibitor. By blocking the action of the enzyme thymidylate synthase, raltitrexed interferes with the synthesis of thymidine, a crucial component of DNA. This inhibition leads to a depletion of thymidine triphosphate, which is essential for DNA replication and repair, ultimately causing cancer cells to die.

The drug is administered intravenously. Its efficacy in colorectal cancer has been demonstrated in clinical trials, where it has been shown to improve progression-free survival and, in some cases, overall survival. However, like many chemotherapy agents, raltitrexed is associated with a range of side effects. Common adverse events include myelosuppression (a decrease in blood cell counts), gastrointestinal toxicity such as nausea, vomiting, diarrhea, and stomatitis (inflammation of the mouth), as well as fatigue and skin reactions.

Raltitrexed's mechanism of action makes it a targeted therapy against rapidly dividing cells, a characteristic of cancer cells. While effective, its use is carefully monitored by healthcare professionals to manage potential toxicities and optimize patient outcomes. The decision to use raltitrexed is typically made after considering the stage and type of cancer, the patient's overall health, and the potential benefits versus risks.